Current HIV/AIDS Reports

, Volume 8, Issue 3, pp 133–141 | Cite as

Vitamin D in HIV-Infected Patients

  • Jordan E. LakeEmail author
  • John S. Adams


Observational studies have noted very high rates of low 25(OH)D (vitamin D) levels in both the general and HIV-infected populations. In HIV-infected patients, low 25(OH)D levels are likely a combination of both traditional risk factors and HIV-specific and antiretroviral therapy–specific contributors. Because of this unique risk profile, HIV-infected persons may be at greater risk for low 25(OH)D levels and frank deficiency and/or may respond to standard repletion regimens differently than HIV-uninfected patients. Currently, the optimal repletion and maintenance dosing regimens for HIV-infected patients remain unknown, as do potential benefits of supplementation that may be unique to the HIV-infected population. This paper reviews data published on HIV infection and vitamin D health in adults over the last year.


Vitamin D 25(OH)D 1,25(OH)2HIV ART Efavirenz Tenofovir 



No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95(2):471–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629–37.PubMedCrossRefGoogle Scholar
  3. 3.
    Ginde AA, Scragg R, Schwartz RS, Camargo Jr CA. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc. 2009;57(9):1595–603.PubMedCrossRefGoogle Scholar
  4. 4.
    Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92(1):4–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes. 2008;57(10):2619–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(12):2813–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int. 2009.Google Scholar
  8. 8.
    Hiremath GS, Cettomai D, Baynes M, Ratchford JN, Newsome S, Harrison D, et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler. 2009;15(6):735–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Medicine Io. Dietary reference intakes for calcium and vitamin D. [Brief Report]. 2010 November 2010.Google Scholar
  10. 10.
    Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev. 2006;64(5 Pt 1):226–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Haug C, Muller F, Aukrust P, Froland SS. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis. 1994;169(4):889–93.PubMedCrossRefGoogle Scholar
  12. 12.
    Holick MF. Vitamin D: a D-Lightful health perspective. Nutr Rev. 2008;66(10 Suppl 2):S182–94.PubMedCrossRefGoogle Scholar
  13. 13.
    • Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol. 2011;50(3):194–200. This article provides an informative review of the antiviral and immunomodulatory effects of vitamin D. PubMedCrossRefGoogle Scholar
  14. 14.
    Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci. 2004;29(12):664–73.PubMedCrossRefGoogle Scholar
  15. 15.
    Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest. 2005;35(5):290–304.PubMedCrossRefGoogle Scholar
  16. 16.
    Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia. 2005;48(7):1247–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.PubMedCrossRefGoogle Scholar
  18. 18.
    Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364(3):248–54.PubMedCrossRefGoogle Scholar
  20. 20.
    Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26(5):662–87.PubMedCrossRefGoogle Scholar
  21. 21.
    Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr. 1995;125(6 Suppl):1704S–8S.PubMedGoogle Scholar
  22. 22.
    Rausch-Fan X, Leutmezer F, Willheim M, Spittler A, Bohle B, Ebner C, et al. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol. 2002;128(1):33–41.PubMedCrossRefGoogle Scholar
  23. 23.
    Girasole G, Wang JM, Pedrazzoni M, Pioli G, Balotta C, Passeri M, et al. Augmentation of monocyte chemotaxis by 1 alpha,25-dihydroxyvitamin D3. Stimulation of defective migration of AIDS patients. J Immunol. 1990;145(8):2459–64.PubMedGoogle Scholar
  24. 24.
    Orikasa M, Kawase T, Suzuki A. Induction of macrophagic and granulocytic differentiation of murine bone marrow progenitor cells by 1,25-dihydroxyvitamin D3. Calcif Tissue Int. 1993;53(3):193–200.PubMedCrossRefGoogle Scholar
  25. 25.
    Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117(3):803–11.PubMedCrossRefGoogle Scholar
  26. 26.
    Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–3.PubMedCrossRefGoogle Scholar
  27. 27.
    Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, et al. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol. 2009;182(7):4289–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Soderlund J. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res. 2007;5(4):410–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Steinstraesser L, Tippler B, Mertens J, Lamme E, Homann HH, Lehnhardt M, et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology. 2005;2:2.PubMedCrossRefGoogle Scholar
  30. 30.
    Hong P, Corcoran K, Modlin R, Lee B, Krutzik S. HIV-1 ssRNA triggers a vitamin D-dependent antiviral pathway in human monocytes. 15th Conference on Retroviruses and Opportunistic Infections Boston, Massachusetts. 2008 February 2008.Google Scholar
  31. 31.
    Conesa-Botella A, Mathieu C, Colebunders R, Moreno-Reyes R, van Etten E, Lynen L, et al. Is vitamin D deficiency involved in the immune reconstruction inflammatory syndrome. AIDS Res Ther. 2009;6(4):1–5.Google Scholar
  32. 32.
    Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24(11):1375–82.PubMedCrossRefGoogle Scholar
  33. 33.
    Garcia Aparicio AM, Munoz Fernandez S, Gonzalez J, Arribas JR, Pena JM, Vazquez JJ, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol. 2006;25(4):537–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Rodriguez M, Daniels B, Gunawardene S, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25(1):9–14.PubMedCrossRefGoogle Scholar
  35. 35.
    Wasserman P, Rubin DS. Highly prevelent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDS. 2010;24(4):223–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Bang UC, Shakar SA, Hitz MF, Jespersen MS, Andersen O, Nielsen SD, et al. Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. Scand J Infect Dis. 2010;42:306–10.PubMedCrossRefGoogle Scholar
  37. 37.
    Ahmed S, Zinkiewicz P, Ninivaggi M, Verley J, Yasmin T, Khan I, Feleke G, et al. Prevalence of vitamin D deficiency in HIV population: an analysis of NHANES. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 2010.Google Scholar
  38. 38.
    Bischof MG, Heinze G, Vierhapper H. Vitamin D status and its relation to age and body mass index. Horm Res. 2006;66(5):211–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab. 2004;89(3):1196–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52(3):396–405.PubMedCrossRefGoogle Scholar
  41. 41.
    Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010;7(40):1–6.Google Scholar
  42. 42.
    Mehta S, Giovannucci EL, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One. 2010;5(1):1–7.CrossRefGoogle Scholar
  43. 43.
    Borderi M, Vescini F, Cozzi-Lepri A, Di Caro A, Shlacht I, Cassola G, et al. Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large italian cohort. 17th conference on retroviruses and opportunistic infections San Francisco, California. [Abstract]. 2010 February 2010.Google Scholar
  44. 44.
    Adeyemi OM, Agniel D, French A, Weber K, Tien PC, Glesby M, et al. High rates of vitamin D deficiency among HIV-infected and at-risk women in the United States. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.Google Scholar
  45. 45.
    Kosmiski LA, Bacchetti P, Kotler DP, Heymsfield SB, Lewis CE, Shlipak MG, et al. Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab. 2008;93(1):216–24.PubMedCrossRefGoogle Scholar
  46. 46.
    Brown TT, Xu X, John M, Singh J, Kingsley LA, Palella FJ, et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther. 2009;6:8.PubMedCrossRefGoogle Scholar
  47. 47.
    Boodram B, Plankey MW, Cox C, Tien PC, Cohen MH, Anastos K, et al. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS. 2009;23(12):1009–16.PubMedCrossRefGoogle Scholar
  48. 48.
    Haug CJ, Aukrust P, Haug E, Morkrid L, Muller F, Froland SS. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83(11):3832–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Hanevold CD, Yamaguchi DT, Jordan SC. Tumor necrosis factor alpha modulates parathyroid hormone action in UMR-106-01 osteoblastic cells. J Bone Miner Res. 1993;8(10):1191–200.PubMedCrossRefGoogle Scholar
  50. 50.
    Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17(4):513–20.PubMedCrossRefGoogle Scholar
  51. 51.
    Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol. 2009;75(6):1392–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004;44(11):1273–81.PubMedCrossRefGoogle Scholar
  53. 53.
    Gyllensten K, Josephson F, Lidman K, Saaf M. Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS. 2006;20(14):1906–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003;46(4):221–7.PubMedCrossRefGoogle Scholar
  55. 55.
    de Luis DA, Bachiller P, Aller R, de Luis J, Izaola O, Terroba MC, et al. Relation among micronutrient intakes with CD4 count in HIV infected patients. Nutr Hosp. 2002;17(6):285–9.PubMedGoogle Scholar
  56. 56.
    Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al. High Prevalence of Severe Vitamin D Deficiency in Combined Antiretroviral Therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24(8):112701134.CrossRefGoogle Scholar
  57. 57.
    Crutchley R, Crutchley R Jr. Risk factors for vitamin D deficiency in HIV. Risk factors for vitamin D deficiency in HIV-1 infected adults in the South-Central United States Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.Google Scholar
  58. 58.
    Gandhi V, Kim JH, Psevdos G Jr, Espinoza F, Park J, Sharp V. Evaluation of vitamin D levels in HIV-infected patients at the Center of Comprehensive Care, St Luke´s Roosevelt Hospital Center, New York, USA. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.Google Scholar
  59. 59.
    Stein EM, Yin MT, McMahon DJ, Shu A, Zhang CA, Ferris DC, et al. Vitamin D deficiency in HIV-infected Postmenopausal Hispanic and African-American Women. Osteoporos Int. 2010;10:1–11.Google Scholar
  60. 60.
    Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24(12):1923–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Allavena C. Delpierre C, Rey D, Cuzin L, Duvivier C, Viget N, et al. Effects of ARV on vitamin D concentration in HIV-infected patients: a large prospective cohort analysis. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2–11 February 27-March 2, 2011.Google Scholar
  62. 62.
    Ross A, Judd SE, Hileman C, Labbato D, Storer N, Tangpricha V, et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-infected individuals. Antivir Ther. in press.Google Scholar
  63. 63.
    Mehta S, Spiegelman D, Magusi F, Giovanucci E, Msmanga G, Fawzi W. Vitamin D HIV-related complications and HIV disease progression in women in Tanzania. Program and abstracts of the 17th Conference on Retroviruses and Opportuistic Infections (San Francisco, CA). [Abstract]. 2010.Google Scholar
  64. 64.
    Childs K, Fishman S, Factor S, Dieterich D, Mullen M, Branch A. First Report of Dose/Response Data of HIV-infected Men Treated with Vitamin D3 Supplement. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.Google Scholar
  65. 65.
    Havens P, Hazra R, Stephensen C, van Loan M, Rutledge B, Bethel J, et al. Vitamin D3 supplementation decreases PTH in HIV-infected youth being treated with TDF-containing combination ART: a randomized, double-blind, placebo-controlled multicenter trial: Adolescent Trials Network Study 063. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.Google Scholar
  66. 66.
    Longenecker C, Hileman C, Carman C, Ross A, Tangpricha V, Seydafkan S, et al. Vitamin D supplementation and endothelial function among vitamin D-deficient HIV-infected persons: a randomized placebo-controlled trial Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.Google Scholar
  67. 67.
    Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15(3):425–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in Vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retroviruses. 2010;26(11):1–6.Google Scholar
  69. 69.
    Lattuada E, Lanzafame M, Zoppini G, Concia E, Vento S. No influence of nevirapine on Vitamin D deficiency in HIV-infected patients. AIDS Res Hum Retroviruses. 2009;25(8):849–50.PubMedCrossRefGoogle Scholar
  70. 70.
    Wohl D, Doroana M, Orkin C, Pilotto JH, Sungkanuparph S, Yeni P, et al. Change in vitamin D levels smaller and risk of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive, adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.Google Scholar
  71. 71.
    Portale AA, Halloran BP, Morris Jr RC. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest. 1989;83(5):1494–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS. 2005;19(17):2031–3.PubMedCrossRefGoogle Scholar
  73. 73.
    Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23(6):689–96.PubMedCrossRefGoogle Scholar
  74. 74.
    • Childs KE, Fishman SL, Constable C, Gutierrez JA, Wyatt CM, Dieterich DT, et al. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses. 2010;26(8):855–9. This manuscript details a well-performed, cross-sectional, observational study, highlighting the independent associations of 25(OH)D and tenofovir use with PTH in HIV-infected patients on ART. PubMedCrossRefGoogle Scholar
  75. 75.
    Pocaterra D, Ricci E, Carenzi L, Schiavini M, Meraviglia P, Minisci D, et al. Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients. Abstracts from the 18th International AIDS Conference Vienna, Austria. 2010 July 21, 2010.Google Scholar
  76. 76.
    Gilead. Viread (tenofovir disoproxil fumarate) package insert. 2010.Google Scholar
  77. 77.
    Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.PubMedCrossRefGoogle Scholar
  78. 78.
    Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49(3):298–308.PubMedCrossRefGoogle Scholar
  79. 79.
    Fux C, Hasse B, Opravil M, Cavassini M, Calmy A, Gurtner-delaFuente V, et al. Bone turnover, and in particular osteoclast activity, is increased in patients with confirmed proximal renal tubulopathy within the Swiss HIV Cohort Study. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.Google Scholar
  80. 80.
    Wirz S, Rubeli S, Christen A, Popp A, Largiadèr C, Mueller N, et al. Renal phosphate wasting and increased bone turnover in tenofovir-treated patients are not mediated by low 25(OH) Vitamin D or hyperparathyroidism. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.Google Scholar
  81. 81.
    Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010;54(5):496–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Labarga P, Barreiro P, Martin-Carbonero L, Alvarez E, Solera C, Pinilla J, et al. Prevalence and mechanisms of hyperparathyroidism in HIV+ patiens treated with TDF. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 Februrary 27-March 2, 2011.Google Scholar
  83. 83.
    Paul TV, Asha HS, Thomas N, Seshadri MS, Rupali P, Abraham OC, et al. Hypovitaminosis D and bone mineral density in HIV infected Indian men with or without antiretroviral therapy. Endocr Pract. 2010;16(4):547–53.PubMedCrossRefGoogle Scholar
  84. 84.
    Marco Borderi FV, Cozzi-Lepri A, Di Caro A, Shlacht I, Cassola G, Pellizzer G, et al. Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large Italian Cohort. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.Google Scholar
  85. 85.
    Rachid T, Devitt E, Meyron I, Mandalia S, Waters L, Bower M, et al. No association of vitamin D levels with individual antiretroviral agents, duration of HIVinfection, alkaline phosphatase levels nor bone mineral density findings. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.Google Scholar
  86. 86.
    Campbell G, Stephen S. 1,25-dihydroxycholecalciferol triggers autophagy in human macrophages that inhibits productive HIV-1 Iinfection. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.Google Scholar
  87. 87.
    Campbell G, Stephen S. Vitamin D3 triggers autophagy in human macrophages that inhibits productive HIV-1/TB co-infection. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.Google Scholar
  88. 88.
    Szep Z, Guaraldi G, Shah SS, Lo Re V 3rd, Ratcliffe SJ, Orlando G, et al. Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS. 2011;25(00).Google Scholar
  89. 89.
    Guaraldi G, Zona S, Orlando G, Carli F, Ligabue G, Stentarelli C, et al. Vitamin D3 supplementation decreases the risk of diabetes mellitus among patients with HIV infection. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.Google Scholar
  90. 90.
    Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract. 1995;27(3):181–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J. 2000;47(4):383–91.PubMedCrossRefGoogle Scholar
  92. 92.
    Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209(4458):823–5.PubMedCrossRefGoogle Scholar
  93. 93.
    Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology. 1986;119(1):84–90.PubMedCrossRefGoogle Scholar
  94. 94.
    Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology. 1983;113(4):1511–8.PubMedCrossRefGoogle Scholar
  95. 95.
    Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–74.PubMedCrossRefGoogle Scholar
  96. 96.
    Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, et al. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr. 2010;53(2):202–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Shahar E, Hassoun G, Kedem E, Pollack S. Low vitamin D levels and bone density changes in young HIV+ Israeli women Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.Google Scholar
  98. 98.
    Choi AI, Lo JC, Mulligan K, Schnell A, Kalapus SC, Li Y, et al. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis. 2011;52(7):941–4.PubMedCrossRefGoogle Scholar
  99. 99.
    Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD, Cole DE, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ. 2010;182(12):E610–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Center for Clinical AIDS Research and EducationDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.UCLA-Orthopaedic Hospital Research CenterDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations